Hepatitis B after liver transplantation is often fatal, and no proven medical therapy exists for this condition. We chose to study the potential efficacy of lamivudine therapy for patients with chronic hepatitis B after liver transplantation. Fifty-two patients with chronic hepatitis B after liver t
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation
✍ Scribed by D. Seehofer; N. Rayes; R. Neuhaus; T. Berg; A. R. Müller; W. O. Bechstein; P. Neuhaus
- Book ID
- 105841008
- Publisher
- Springer
- Year
- 2000
- Tongue
- English
- Weight
- 62 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0934-0874
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low-dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had
Immunoprophylaxis using intravenous (IV) hepatitis B immune globulin (HBIG) decreases the recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). However, IV HBIG is expensive, has significant side effects, and is inconvenient to administer. An alternative appro
## Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). Eighteen of 20 patients with insufficient response to FCV were treated with 100 mg LAM daily after OLT. These patients had s